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The gut mucosa is constantly challenged by a bombardment of foreign antigens and envi-
ronmental microorganisms. As such, the precise regulation of the intestinal barrier allows
the maintenance of mucosal immune homeostasis and prevents the onset of uncontrolled
inflammation. In support of this concept, emerging evidence points to defects in compo-
nents of the epithelial barrier as etiologic factors in the pathogenesis of inflammatory bowel
diseases (IBDs). In fact, the integrity of the intestinal barrier relies on different elements,
including robust innate immune responses, epithelial paracellular permeability, epithelial
cell integrity, as well as the production of mucus. The purpose of this review is to sys-
tematically evaluate how alterations in the aforementioned epithelial components can lead
to the disruption of intestinal immune homeostasis, and subsequent inflammation. In this
regard, the wealth of data from mouse models of intestinal inflammation and human genet-
ics are pivotal in understanding pathogenic pathways, for example, that are initiated from
the specific loss of function of a single protein leading to the onset of intestinal disease.
On the other hand, several recently proposed therapeutic approaches to treat human IBD
are targeted at enhancing different elements of gut barrier function, further supporting a
primary role of the epithelium in the pathogenesis of chronic intestinal inflammation and
emphasizing the importance of maintaining a healthy and effective intestinal barrier.
Keywords: intestinal epithelial cells, intestinal barrier function, gut immune homeostasis, innate immunity, Crohn’s
disease, ulcerative colitis, inflammatory bowel disease genetics, animal models of intestinal inflammation
INTRODUCTION
The gastrointestinal tract, from the beginning of extrauterine life,
is chronically exposed to a huge burden of foreign antigens, various
microorganisms, and toxic molecules. Therefore, its ability to act
as a barrier against potentially harmful molecules and to defend
against pathogenic bacteria is pivotal in maintaining gut immune
homeostasis. In fact, evolution has selected different mechanisms
by which the gut serves as an effective protective barrier. Of para-
mount importance is the intestinal epithelium of which intestinal
epithelial cells (IECs) are the primary cell type coming into con-
tact with the external environment and act as the host’s first line
of the defense against potential harmful stimulants. Despite their
non-hematopoietic derivation, IECs also represent a core element
of innate immunity within the gut mucosa, displaying a wide array
of immune functions. In fact, IECs are able to recognize pathogens
through the expression of innate immune receptors, to release
anti-microbial molecules, and to secrete cytokines and chemokines
that link innate and adaptive immune responses. Moreover, IECs
also represent the main structural component of the physical bar-
rier between the luminal microenvironment and host, allowing
selective absorption of nutrients and denying entry of noxious
molecules and antigens. The intestinal epithelium constitutes the
largest exposed surface area of the human body and its perme-
ability is finely regulated by the presence of tight junctions (TJs),
large molecular complexes which, together with adherens junc-
tions (AJs), link IECs to each other, and seal the intercellular spaces
on the luminal surface, regulating molecule passage through the
paracellular spaces. Finally, IECs produce the mucus layer cover-
ing the entire length of the gastrointestinal tract, whose role is
to further protect the mucosal surface from harmful molecules
and bacteria, and reinforce the overall intestinal barrier. As such,
any defect in these IEC-specific processes can cause a breakdown
in gut barrier and consequently, a disruption of normal mucosal
immune homeostasis that can potentially lead to uncontrolled
chronic inflammation, such as that observed in inflammatory
bowel disease (IBD).
DEFECTS IN EPITHELIAL-SPECIFIC INNATE IMMUNE
FUNCTIONS LEAD TO INTESTINAL INFLAMMATION
Intestinal epithelial cells, located at the interface between the exter-
nal environment and the internal mucosal immune system, must
be able to mount early and appropriate defense responses against
various pathogens in order to maintain homeostasis. Central to
this process are innate immune receptor molecules, referred to as
pattern-recognition receptors (PRRs), whose function is to sense
highly conserved structures or pathogen-associated molecular pat-
terns (PAMPs) present among several different pathogens (1).
Archetypal molecules belonging to PRRs are the toll-like receptors
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(TLRs), which are type I integral transmembrane glycoproteins
expressed by several types of cells, including IECs. The TLR fam-
ily consists of at least 13 members with slightly different struc-
tures that recognize, through an extracellular domain containing
large leucine-rich repeats, different PAMPs, such as lipopolysac-
charide (LPS), peptidoglycan (PGN), muramyl dipeptide (MDP),
lipoteichoic acids (LTAs), and bacterial DNA (2). Recognition of
each TLR-specific PAMP initiates downstream signaling through
two different pathways: via the myeloid differentiating factor 88
(MyD88) pathway and via an alternative “MyD88-independent”
pathway, both of which lead to activation of NF-κB, trigger-
ing of other innate immune responses, production of cytokines
and chemokines, and finally, recruitment of the adaptive immune
system (2). Interestingly, the MyD88 pathway is activated by a cyto-
plasmic domain similar to the interleukin-1 receptor (IL-1R) (3),
and both TLR and IL-1R stimulation leads to NF-κB activation (4).
GENETICALLY ENGINEERED MODELS AFFECTING EPITHELIAL INNATE
RESPONSES
Several lines of evidence using genetically manipulated mouse
models suggest that deletion/dysregulation of genes and specific
chromosomal loci associated with epithelial barrier function can
lead to chronic intestinal inflammation (Figure 1). In fact, epithe-
lial barrier defects are clearly present in most animal models of
IBD (summarized in Table 1), which have become seminal tools
in understanding normal epithelial physiology as well as the role
of IECs in the development of gut inflammation.
Toll-like receptor-bearing IECs are of critical importance for
organizing the first line defense against pathogenic microorgan-
isms and in maintaining normal barrier function. For example,
the development of spontaneous intestinal inflammation has been
reported in TLR5 knockout (KO) mice, with around 35–40% of
these mice presenting with colitis and exhibiting areas of extensive
mononuclear infiltration, epithelial hyperplasia, and focal epithe-
lial crypt destruction (5). An increase in intestinal permeability
was also noted in this model, even though it appeared to be sec-
ondary to the inflammatory process and not the triggering event.
Instead, the primary defect leading to colitis in these mice is spec-
ulated to be the waning ability to clear bacteria due to an inherent
defect in innate immune responses. Thus, the lack of TLR5 pro-
motes an increase in colonic bacterial burden, and this process
may enhance the activation of other proinflammatory pathways.
In fact, the absence of colonic inflammation in TLR4/5 and IL-
1R/TLR5 double KO mouse strains (5, 6) strongly suggests that
activation of other Toll/IL-1 receptor pathways, such as TLR4 and
IL-1R, is essential for the onset of disease.
The importance of TLR5 signaling in the development of spon-
taneous gut inflammation has also been brought to light using the
spontaneous C3H/HeJBir model of colitis as well as studies in IBD
patients, which suggest a central role for TLR5 and bacterial fla-
gellin, its natural ligand, in the pathogenesis of Crohn’s disease
(CD), one of the major forms of IBD. The colitis characteristic of
C3H/HeJBir mice is primarily localized to the cecum and resolves
by 3 months of age (7). Interaction with the commensal bacter-
ial flora is important in this model, as innate responses to TLR
ligands are impaired compared to the colitis-resistant C57BL/6
strain (8), with the major class of antigens identified as commensal
bacterial flagellins, recognized by TLR5 (9). In fact, serum IgG anti-
flagellin antibodies have been identified in three different mouse
models and in approximately 50% of CD patients evaluated, but
not in either UC patients or controls (9). In addition, flagellin-
reactive Th1 cells isolated from C3H/HeJBir mice have the ability
FIGURE 1 | Murine loci and genes associated with gut inflammation
that are potentially related to intestinal epithelial barrier
dysfunction. Colitis susceptibility loci, Cdcs, and Dssc, are identified by
red bold font. Genes potentially involved in the epithelial barrier defect
characteristic of SAMP mice are italicized. Genes deleted in mouse
models of intestinal inflammation that affect epithelial function are
underscored. The potential role of each gene in the pathogenesis of
epithelial dysfunction associated with chronic intestinal inflammation is
discussed within the text. Cdcs, cytokine deficiency-induced colitis
susceptibility; Dssc, DSS colitis locus.
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Table 1 | Inflammatory bowel disease animal models with primary defects of intestinal epithelial origin.
Animal model Disease location/
phenotype of
inflammation
Histologic features Identified
gene(s) involved
Epithelial-specific dysfunction
CHEMICALLY INDUCED MODELS
DSS-induced
colitis (57)
Superficial colitis Superficial ulcerations Loci increasing susceptibility
to the induced model found
on Chr5 and Chr2
Chemical destruction of mucosal
barrier with consequent increase in
luminal bacterial translocation
Infiltration of acute inflammatory
cells
Crypt distortion
Loss of goblet cells
TNBS-induced
colitis (61)
Transmural colitis Ulceration N/A Ethanol-induced destruction of
mucosal barrier facilitating hapten
penetration and contact with
underlying mucosal immune system
Infiltration of acute/chronic
inflammatory cells
Crypt distortion
Loss of goblet cells
GENETICALLY ENGINEERED MODELS AFFECTING EPITHELIAL BARRIER INTEGRITY
Mdr1a
knockout (103)
Transmural colitis Colonic thickening with crypt
hyperplasia
Mdr1a deletion Increased basal colonic ion
transport
Focal ulcerations Dysregulated epithelial cell growth
Crypt abscesses
Leukocyte infiltration
Increased number of granulocytes
Increased permeability (dependent
on bacterial colonization
Decreased phosphorylation of TJ
proteins (ZO-1 and occludin)
Dominant
negative
N-cadherin
transgenic (62)
Patchy foci of ileal
inflammation
Cryptitis and crypt abscesses
Epithelial hyperplasia
Presence of lymphoid aggregates
Dominant negative
N-cadherin expression in
small intestinal IEC
Breakdown of intestinal epithelial
apical junctional complexes
Aberrant cell migration,
proliferation, and apoptosis in small
intestinal crypts
Gai2 knockout
(64)
Superficial pancolitis;
increased severity in
distal colon
Cryptitis and crypt abscesses with
crypt distortion
Gai2 deletion Possible impairment of epithelial TJ
assembly
Mucosal PMN infiltrates
JAM-A
knockout (66)
Colitis Normal epithelial architecture
Increased PMN infiltration
Formation of large lymphoid
aggregates
JAM-A deletion Impaired TJ structure and
consequent increase in epithelial
permeability
Increase in the TJ proteins,
claudin-10 and -15
GENETICALLY ENGINEERED MODELS AFFECTING EPITHELIAL INNATE RESPONSES
TLR5 knockout
(5)
Colitis; 10% incidence
of rectal prolapse
Mononuclear infiltrates
Epithelial hyperplasia
Focal crypt loss
Goblet cell depletion
TLR5 deletion Increased epithelial permeability
(secondary to inflammation)
Ineffective bacterial clearance
NEMOIEC-KO
(23)
Pancolitis Mucosal thickening
Enlarged crypts
Loss of goblet cells
Extensive epithelial destruction
Marked infiltration of mononuclear
cells in mucosa/submucosa
IEC-specific inhibition of
NF-κB via conditional ablation
of NEMO (IKKg)
Colonic epithelial cell apoptosis (via
increased sensitivity to TNF)
Impaired expression of
anti-microbial peptides
Dysregulated epithelial barrier
integrity
TAK1IEC-KO (24) Enterocolitis Complete disruption of small
intestine structure
IEC specific conditional
ablation of TAK1
Colonic epithelial cell apoptosis (via
increased sensitivity to TNF)
Less severe alterations of colonic
tissue
Impaired innate immune response
(Continued)
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Table 1 | Continued
Animal model Disease location/
phenotype of
inflammation
Histologic features Identified
gene(s) involved
Epithelial-specific dysfunction
GENETICALLY ENGINEERED MODELS AFFECTING EPITHELIAL CELL INTEGRITY AND MUCUS PRODUCTION
XBP1IEC-KO
(100)
Focal
non-granulomatous
enteritis
Absence of Paneth cells
Loss of goblet cells
Lamina propria mononuclear
infiltrate
Crypt abscesses
Mucosal ulcerations
Villus shortening with a reduction of
villus:crypt ratio
IEC specific conditional
ablation of XBP1
Impaired innate immune response
due to Paneth cell loss by apoptosis
Endoplasmic reticulum (ER) stress
secondary to the lack of XBP1
Increased proinflammatory
signaling due to increased
JNK/SAPK activation secondary to
the lack of XBP1
AP1M2
knockout (98)
Transmural colitis Epithelial hyperplasia Epithelia-specific membrane
trafficking factor AP-1B
deficiency induced via AP1M2
deletion
Loss of IEC polarity
Crypt distorsion
Loss of goblet cells
Mucosal and submucosal
inflammatory infiltrate
Impaired epithelial production of
anti-microbial peptides
Defective luminal transport of
secretory IgA
GENETICALLY ENGINEERED MODELS AFFECTING EPITHELIAL CELL INTEGRITY AND MUCUS PRODUCTION
RBP-JIEC-KO
(99)
Colitis; rectal prolapse Goblet cell hyperplasia IEC-specific impairment of
Notch signaling via conditional
ablation of RBP-J
Retarded IEC turnover
Aberrant accumulation of mucus
under the tunica serosa
Neutrophilic infiltrate
Increased epithelial permeability
Impaired epithelial defense against
bacteria
MUC2
knockout (123)
Superficial colitis; more
severe in the distal
colon
Complete lack of goblet cells MUC2 deletion Altered bacterial stimulation of IECs
due to a diminished mucus layerCrypt hyperplasia
Flattening of the epithelial layer and
superficial erosions
Mild inflammatory infiltration
Lamina propria distorsion
MUC2 mutant
(Winnie and
Eeyore strains)
(124)
Superficial colitis; more
severe in the distal
colon
Focal epithelial erosions
Crypt elongation
MUC2 missense mutations Altered bacterial stimulation of IECs
due to a diminished mucus layer
Increased endoplasmic reticulum
(ER) stress due to mutated MUC2
protein misfolding and accumulation
in ER
Neutrophilic infiltrate
Crypt abscesses
Goblet cell loss
POFUT1IEC-KO
(128)
Enterocolitis Crypt hyperplasia IEC specific conditional
ablation of POFUT1
Notch signaling impairment with
consequent goblet cell hyperplasia
and mucus hypersecretion, leading
to associated gut microbiota
alterations
Dilated and mucus filled crypts
Hyperplasia of Paneth cells and
enteroendocrine cells
Inflammatory infiltrate of the lamina
propria
Crypt abscesses
Transmural inflammation
SPONTANEOUS MODELS
SAMP1/YitFc
(74)
Segmental,
discontinuous,
transmural ileitis;
increased severity in
the terminal ileum with
2–3% incidence of
perianal disease
Villous blunting/crypt hypertrophy
Paneth cell/goblet cell hyperplasia
PMN/mononuclear cell infiltration in
lamina propria and submucosa
Aphthous inflammatory lesions
Granuloma formation
Cryptitis/crypt microabscesses
Basal plasmacytosis
Multigenic etiology;
susceptibility found on Chr6,
Chr8, Chr9, and ChrX
Primary non-hematopoietic (i.e.,
epithelial) dysfunction
Increased epithelial permeability
independent of commensal
bacterial colonization
Altered TJ protein expression
(increase in claudin-2, decrease in
occludin)
Dysregulated epithelial innate
responses
(Continued)
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Table 1 | Continued
Animal model Disease location/
phenotype of
inflammation
Histologic features Identified
gene(s) involved
Epithelial-specific dysfunction
C3H/HeJBir (7) Colitis; primary
localization in the
cecum
Acute and chronic inflammatory
infiltrate
Multigenic etiology;
susceptibility found on Chr3,
Chr1, Chr2, Chr8, Chr17, and
Chr18
Dysregulated epithelial innate
responses
Crypt abscesses Ineffective bacterial clearance
Ulcerations
Regenerative hyperplasia
Hyper-responsiveness to flagellin
stimulation
to induce colitis upon transfer to naïve SCID recipients. Analysis of
quantitative trait locus mapping of C3H/HeJBir mice backcrossed
with IL-10 KO mice identified several potential colitogenic loci on
chromosome 3, 1, 2, 8, 17, and 18, named, respectively, cytokine
deficiency-induced colitis susceptibility 1–6 (Cdcs1–6) (10). The
strongest association with the colitic phenotype was seen for Cdcs1,
which includes two attractive candidate genes: encoding nuclear
factor kappa B subunit 1 (Nfκb1), and encoding guanylate bind-
ing protein 1 (Gbp1) (8). Quite remarkably, both of these genes
encode pivotal proteins in TLR downstream signaling, corrobo-
rating data on the impairment of TLR5. Although a direct link to
epithelial dysfunction has not been made to the colitis phenotype,
these data suggest that C3H/HeJBir mice exhibit defects in TLR5-
dependent host-microflora interactions, resulting in increased T
cell responses to bacterial antigens (i.e., flagellin).
Activation of the TLR5 pathway also appears to be the mech-
anism by which adherent-invasive Escherichia coli (AIEC) exac-
erbates inflammation in dextran sulfate sodium (DSS)-induced
colitis (11). In these studies, BALBc/J mice treated with DSS and
orally challenged with LF82, the reference strain for AIEC that has
the ability to adhere to and invade IECs (12) and notably colo-
nizes the inflamed mucosa of ileal CD patients (13), worsened the
severity of colitis and induced a sevenfold increase in colonic tissue
levels of TLR5 compared to mice infected with a mutated strain
of LF82 that lacks the fliC gene encoding flagellin (11). These data
further support a central role of TLR5 activation in bacterial-host
interactions that drive chronic intestinal inflammation. Moreover,
a dominant-negative TLR5 polymorphism, which has been shown
to dampen adaptive immune responses to flagellin, appears to
reduce the production of IgG against flagellin and to be protective
against the development of CD in a Jewish population, suggesting
that mucosal immune responses to flagellin promote pathogenic
responses in CD (14).
Aside from TLR5, other TLRs, such as TLR4, also appear to
play a role in gut mucosal immune homeostasis and in regu-
lating epithelial barrier function against invasive bacteria. TLR4
and MyD88 KO mice both develop more severe colitis induced
by DSS compared to wildtype (WT) controls, with increased bac-
terial translocation, shown by the greater positivity of mesenteric
lymph node cultures for E. coli and Pseudomonas fluorescence (15).
Remarkably, the analysis of intestinal mucosa from IBD patients
has shown a strong upregulation of TLR4 that is normally not
expressed in healthy individuals (16), while genetic association
studies have linked carriage of the TLR4 Asp299Gly polymor-
phism, which has been reported to impair LPS sensing, with IBD
susceptibility in different patient populations (17). The preva-
lence of other TLR genetic polymorphisms has been reported in
IBD. TLR1, -2, and -6 non-synonymous polymorphisms have also
been shown to be associated with UC and CD colonic disease
extension (18). While mechanistic studies have not been reported
for TLR1 and -6, TLR2 KO mice have been shown to be more
susceptible to DSS colitis than WT controls (19). These mice dis-
play an increase in IEC apoptosis that is secondary to defective
goblet cell production of trefoil factor 3 (TFF3), a peptide with
anti-apoptotic functions that also enhances mucosal healing (20).
Similarly, impairment of TLR9 may also promote the development
of intestinal inflammation. Indeed, IECs constitutively expressing
TLR9 release potent amounts of the proinflammatory cytokines,
TNF, and IL-8, in response to CpG DNA, TLR9’s natural ligand
(21). Nonetheless, while a TLR9 polymorphism has been reported
to be associated with CD (22), more experimental data are war-
ranted to clarify the role of TLR9- and other TLR-dependent
pathways in the pathogenesis of IBD.
Downstream of TLR signaling, NF-κB activation occurs that
results in the initiation of a proinflammatory cascade. Increasing
evidence suggests that the NF-κB pathway plays a critical role in
regulating epithelial innate responses and maintaining gut home-
ostasis. This is best illustrated by the NEMO KO model in which
IEC-specific inhibition of NF-κB, through conditional ablation of
NEMO, results in the generation of spontaneous pancolitis (23).
In these mutant mice, specific IEC deletion of NF-κB specifically
resulted in apoptosis of colonic epithelial cells, impaired expres-
sion of anti-microbial peptides, and increased translocation of
bacteria into the gut mucosa. In addition, deficiency of the gene
encoding MyD88, positioned upstream of NEMO in the NF-κB
signaling cascade, prevented colitis and demonstrates that TLR
activation by the gut microbiota is essential for disease patho-
genesis in this model (23). Similarly, TGF-β-activated kinase 1
(TAK1) is an essential intermediate of innate signaling pathways,
and its expression also leads to downstream NF-κB activation. Spe-
cific deletion of TAK1 in IECs results in death on postnatal Day
1 in mutant mice, due to severe intestinal bleeding, while TAK1
knockdown in 4-week-old mice leads to the onset of intestinal
inflammation, characterized by a complete loss of small intestinal
architecture and a marked increase in IEC apoptosis within the
crypts of both the ileum and colon (24). In this model however,
impairment of innate immunity due to ineffective downstream
TLR signaling is not the only mechanism proposed to induce
the aforementioned gut pathologies. In fact, double mutant mice,
bearing both the intestinal epithelium-specific TAK1 deletion and
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the tumor necrosis factor receptor 1 (TNFR1) deletion develop less
severe gut inflammation and IEC apoptosis, suggesting that TAK1
confers IEC resistance toward TNF-mediated apoptosis during the
inflammatory process (24). Taken together, these data indicate that
NF-κB not only serves as a master regulator of proinflammatory
cytokines, but also functions to control epithelial barrier integrity
and interactions between the mucosal immune system and the
gut microflora. The role, however, of the TLR/NF-κB pathway in
the development of IBD is complex and may be cell-specific in
its overall contribution to disease pathogenesis. In fact, whereas
TLR/NF-κB engagement on IECs appears to be mostly protective,
the activation of the same pathway in cells participating to adaptive
immunity is more likely to contribute to intestinal inflammation.
IBD SUSCEPTIBILITY GENES ASSOCIATED WITH EPITHELIAL INNATE
IMMUNE FUNCTIONS
Emerging evidence suggests that human genetic studies investigat-
ing the pathogenesis of IBD strongly corroborate the hypothesis
of a fundamental influence of innate immunity in maintaining
gut mucosal immune homeostasis. In fact, apart from genes asso-
ciated with the TLR pathway, the most convincing genetic data
linking dysregulated innate immune responses with IBD cen-
ters around genes of the caspase recruitment domain/nucleotide-
binding oligomerization domain (CARD/NOD) family, as well as
autophagy-related genes.
CARD15/NOD2 was the first CD susceptibility gene identified
in 2001 (25, 26); the discovery of its association to CD ignited
interest in the potential mechanistic defects of innate immu-
nity in the pathogenesis of IBD. CARD15/NOD2 is located on
chromosome 16 and encodes a cytoplasmic protein constitutively
expressed in myeloid cells (27), IECs, and Paneth cells of the
small bowel (28). The CARD15/NOD2 protein is a PRR involved
in recognition of the bacterial cell wall component, MDP (29,
30). Similar to other PRRs, sensing of MDP by CARD15/NOD2
triggers NF-kB activation and subsequent expression of proin-
flammatory cytokines, including TNF, IL-1, IL-6, IL-8, and IL-18
(27, 30, 31). CARD15/NOD2 is also critical for the release of α-
defensins (HD5 and HD6) from Paneth cells (32–34); defensins
are anti-microbial peptides synthesized by epithelial cells from the
skin, urogenital tract, intestine, and lung (35), whose role is to
protect mucosal surfaces by killing pathogens (33, 34). Polymor-
phisms of TCF-4, a transcription factor involved in Paneth cell
differentiation and HD5 and HD6 expression, have been reported
to be associated with ileal CD (36). On the same line, ileal CD
patients carrying CARD15/NOD2 disease-associated variants dis-
play impaired mucosal expression of α-defensins (34, 37), and
reduced ability of colonic IEC to excrete β-defensins, in partic-
ular human β-defensin 2, in response to MDP (38). The defect
in defensin release and IEC response to bacterial challenge may
represent a pivotal event in the onset of IBD. In fact, Paneth cells
capable of producing high levels of IL-17 if adequately stimu-
lated with TNF have been described (39), that may occur as a
result of defective bacterial killing and instead, activation by pen-
etrating pathogens. The IL-23/IL-17 axis has been shown to be
involved in autoimmune inflammation, both in humans and ani-
mal models (40–42), including IBD (43). Thus, bacterial clearance
promoted by CARD15/NOD2 activation appears to be mandatory
for maintaining intestinal epithelial barrier function. Nonetheless,
other studies suggest that bacterial killing may not be the only
mechanism by which CARD15/NOD2 enhances epithelial bar-
rier function. In fact, several studies showed that CARD15/NOD2
variants are associated with increased intestinal permeability in
CD patients and their relatives (34, 44–46); however, the precise
mechanism(s) linking a PRR defect and increased intestinal per-
meability are still largely unknown. Finally, another member of
the CARD/NOD family, CARD4/NOD1 that encodes an intracel-
lular receptor with the ability to recognize a unique tripeptide
motif (diaminopimelic acid) found in Gram-negative bacterial
PGN (47), has been proposed as an IBD susceptibility gene, since
three polymorphic variants have been reported to be associated
with IBD in two different Caucasian populations (48), adding
further interest to the PPR pathways.
Although less developed than the evidence supporting a role for
CARD15/NOD2 in the pathogenesis of IBD, recent genetic find-
ings have focused on the importance of another branch of innate
immunity, that is autophagy, in the regulation of intestinal inflam-
mation. Indeed, large genome-wide association studies have iden-
tified two autophagy-related genes, autophagy-related 16-like 1
(ATG16L1) (49) and immunity-related GTPase family M (IRGM )
(50) on chromosomes 2 and 5, respectively, as CD susceptibility
genes. Autophagy is a intracellular process through which cells
rearrange their cytoplasm and organelles by means of lysosomal
digestion (51), and is considered a response of innate immunity
as it represents a major mechanism of defense against intracellular
pathogens, such as Salmonella or Mycobacterium species (49, 52,
53). In fact, functional studies have shown that ATG16L1 knock-
down in IEC lines impairs the clearance S. typhimurium infection
(49). In addition, since cells undergo a structural de-arrangement
during the autophagic process, autophagy has the potential to
alter overall epithelial integrity (51). Interestingly, mice that are
genetically engineered to under-express the ATG16L1 protein dis-
play profound alterations in Paneth cell morphology and function
(54). Although these mice do not develop spontaneous gut inflam-
mation, they show a lack of lysozymes in the intestinal mucus,
hyperactivation of proinflammatory pathways,and the production
of adipokines and acute phase reactants (54).
Taken together, epithelial innate immune function, includ-
ing appropriate activation of PRR pathways and of autophagy
processes, plays a central role in the overall maintenance of intesti-
nal immune homeostasis. Defects in epithelial innate function
can result in dysregulated mucosal immune responses that lead
to chronic intestinal inflammation and IBD (Figure 2). As such,
IECs embody much more than the mere lining of the gut lumen,
but represent the first line of host defense, controlling penetration,
and invasion of pathogens, which is critical in limiting adaptive
immune activation.
DEFECTS IN EPITHELIAL BARRIER FUNCTION LEAD TO
INTESTINAL INFLAMMATION
In addition to the central role of IECs in maintaining mucosal bar-
rier function through early activation of innate immune responses,
the intestinal epithelium also constitutes an impermeable layer
that has the ability to selectively absorb what is necessary to sus-
tain the organism, while denying passage of other pathogenic and
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FIGURE 2 | Epithelial innate immune function is a key factor in
maintaining gut homeostasis. IECs express PRRs, such as TLRs and
NOD-like receptors, whose signaling activates NF-κB, leading to
reinforcement of the epithelial barrier through release of anti-microbial
peptides (i.e., defensins) and paracellular secretion of proinflammatory
cytokines (e.g., TNF, IL-1, and IL-18) that enhance mucosal defense to
bacterial penetration and the production of trophic factors, such as
intestinal TFF3 that can block IEC apoptosis. Autophagy, perhaps due to
ATG16L1, also contributes to the effectiveness of the epithelial barrier,
controlling intracellular pathogens, and inducing lysozyme production.
Breakdown of PRR/NF-κB signaling pathways via critical components,
including MyD88, TAK1, and NEMO, facilitates penetrance of luminal
microorganisms, triggering an exaggerated adaptive immune response.
Similarly, defects in autophagy lead to less effective bacterial clearance and
production of proinflammatory molecules, such as adipokines and acute
phase reactants from Paneth cells.
noxious molecules. Disruption of this selective physical barrier,
resulting in uncontrolled or dysregulated gut epithelial perme-
ability can induce an overactive mucosal immune response and
chronic intestinal inflammation. In fact, since 1972, when Shorter
et al. postulated that a primary defect in intestinal permeability
might lead to the development of persistent inflammation in the
gut, as in the case of IBD (55), a growing body of evidence has
supported this theory. Central to this hypothesis, several studies
have reported ultrastructural changes in IEC junctional complexes,
inducing dramatic changes in gut permeability in both animal
models of intestinal inflammation and IBD patients.
ROLE OF TIGHT JUNCTIONS IN INTESTINAL INFLAMMATION
Tight junctions are pivotal in regulating intestinal permeabil-
ity and the diffusion of ions and molecules across the epithelial
luminal surface. TJs consist of at least 50 different membrane-
associated proteins located between apical and lateral regions
of polarized epithelial cells that link neighboring cells and reg-
ulate molecular flow through intercellular spaces (56). TJ pro-
teins include: (1) integral membrane proteins, such as junctional
adhesion molecules, claudins, and occludins, which extend into
the intercellular spaces and function as a gate, (2) cytoplasmic
cytoskeletal linker proteins, such as cingulin, zona occludens-1,
-2, -3 (ZO-1, -2, -3), which anchor membrane proteins to the
cytoskeleton, and (3) a number of signaling proteins that can acti-
vate various downstream cascades, act as transcription factors, and
serve as cell cycle regulators (56). Several lines of evidence support
the concept that a direct link exists between TJ protein impair-
ment and intestinal inflammation, with the large majority of data
generated from animal models of intestinal inflammation.
IMPAIRED GUT PERMEABILITY IN ANIMAL MODELS OF INTESTINAL
INFLAMMATION
Chemically induced colitis likely represents the most highly uti-
lized animal models to induce intestinal inflammation. A proto-
typic example is colitis induced by DSS, which is fed to directly
damage the colonic epithelium, resulting in disruption of barrier
integrity and a subsequent increase in luminal antigen/bacterial
translocation to the underlying components of the gut mucosal
immune system (57). In fact, mice exposed to DSS develop an
increase in intestinal permeability before the onset of colonic
inflammation. Moreover, several changes in TJ assembly occur
during the pre-inflammatory stage of this model, such as complete
loss of ZO-1 expression and a doubling of occludin-1 expression
in colonic epithelia (58). The ensuing inflammation is acute in
nature, primarily consisting of neutrophil and macrophage infil-
tration and expression of associated cytokines. The sensitivity to
DSS challenge differs in various mouse strains (e.g., C3H/HeJ
mice display increased susceptibility compared to C57BL/6J mice),
while genetic studies have identified quantitative trait loci confer-
ring susceptibility to the development of DSS-induced colonic
inflammation. These loci, named DSS colitis 1 and 2 (Dssc1 and
2), are located on chromosomes 5 and 2, respectively, but further
investigation is needed to evaluate the actual susceptibility genes
within these loci (59). As such, although a viable model to inves-
tigate the process of epithelial damage/repair and the subsequent
acute inflammatory events, it should also be noted that acute DSS
colitis does not require the presence of T and B cells (60), and
therefore, does not represent an appropriate model when inves-
tigating more chronic and adaptive immune responses related to
IBD pathogenesis.
Similarly, trinitrobenzene sulfonic acid (TNBS)-induced coli-
tis is an alternative chemically induced model in which an ethanol
solvent is first administered that permeabilizes the epithelium, fol-
lowed by TNBS that functions as a sensitizing hapten driving
cellular immune responses toward a Th1 polarized phenotype
(61). Despite the artificial nature for initiating gut inflammation,
chemically induced models of colitis highlight the importance of
epithelial barrier disruption, which is likely the primary event lead-
ing to the development of colonic inflammation characteristic of
these models.
Interestingly, while several genetically engineered mouse mod-
els have been commonly challenged with either DSS and/or TNBS
to assess their susceptibility toward a colitic phenotype, only a
few of these mutant mice with deletion or transgenic expression
of genes related to specific junctional complexes develop colitis
spontaneously and without further manipulation. For example,
mice genetically engineered to express a dominant negative N-
cadherin specifically in small intestinal IECs develop a sponta-
neous IBD phenotype resembling CD (62). Cadherins, together
with catenins, are the main constituent of the AJs, cell-to-cell
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adhesion structures, and are essential for normal gut development.
N-cadherin is a transmembrane molecule that regulates calcium-
dependent intercellular adhesion and relies on its association with
the actin cytoskeleton. In these mice, altered expression of N-
cadherin interferes with E-cadherin and leads to ruptures in the
epithelial monolayer and to the generation of patchy inflamma-
tory lesions. N-cadherin mutant mice also demonstrate aberrant
epithelial proliferation, migration, and programed cell death in
small intestinal crypts that eventually lead to adenoma forma-
tion. In support of these data, mice conditionally knocked-out
for epithelial p120-catenin, a direct cytoplasmic regulator of E-
cadherin expression and function, show a phenotype similar to
dominant negative N-cadherin mice (63).
Another IBD model that results from a primary epithelial per-
meability defect is the Gαi2 KO mouse strain that develops a
pancolitis at 8–12 weeks of age, and for which early indications
point to a defective epithelial barrier that occurs prior to histologic
inflammation (64). Gαi2 is an inhibitory isoform of G protein sub-
unit α found in IEC as well as lymphocytes that plays an important
role in regulating signal transduction through adenylate cyclase;
this subunit is also critical in regulating epithelial permeability. In
fact, it has been shown that Gαi2 overexpression in IEC monolayers
induces TJ assembly, increasing transepithelial electrical resistance
(TER) (65). Therefore, a possible impairment of TJ assembly may
be responsible for decreased barrier integrity leading to superfi-
cial colitis, which is most severe in the distal colon of this mouse
strain (64).
Deletion of the JAM-A gene, encoding a transmembrane TJ
protein, has generated a unique model of intestinal inflammation.
JAM-A deficient mice display increased colonic epithelial perme-
ability in homozygous mutants that corresponds to an increase in
claudin-10 and -15 (66). While the colonic mucosa has normal
epithelial architecture, increased polymorphonuclear infiltration,
and formation of large lymphoid aggregates are observed in JAM-A
KO mice that are absent in WT controls (66). JAM-A is also local-
ized to TJs of endothelial cells as well as on the surface of leuko-
cytes, serving as a critical protein in mediating leukocyte migration
(67). However, when mice with specific inactivation of JAM-A in
endothelial and hematopoietic cells (Tie-2-Cre-JAM-A−/− mice)
(68) were treated with DSS, resulting colonic inflammation was
comparable to controls and much less severe than in JAM-A KO
mice, strengthening the hypothesis of a primary defect of epithe-
lial origin that leads to colitis (69). Interesting, in the same study,
reduced levels of JAM-A expression were detected in inflamed
tissues from IBD patients compared to controls (69), suggesting
that JAM-A may also play an important role in human disease.
However, recent studies in JAM-A KO mice have also shown that
dysregulation in adaptive immunity also plays a role in the devel-
opment of the colitis phenotype since the lack of T and B cells
and, more prominently the absence of CD4+ T cells, increases the
severity of intestinal inflammation in these mice (70).
Indeed, the phenotype displayed by the three aforementioned
strains of genetically modified mice suggests a primary involve-
ment of epithelial barrier dysfunction in the pathogenesis of
intestinal inflammation. However, it should be pointed out that,
at present, no other mouse strain in which assembly of the intesti-
nal epithelial junctional structure has been altered, develops any
significant signs of intestinal inflammation. As an example, even
though occludin KO mice exhibit pronounced morphologic alter-
ations within the gastric mucosa, such as mucus cell hyperplasia
and complete loss of parietal cells, no evidence of inflammation
has been detected in both the stomach as well as along the entire
length of the gut (71). Quite surprisingly, the absence of occludin
in these mice does not seem to affect intestinal permeability, which
appears to be comparable to that observed in WT littermates (71).
Similarly, claudin-15 deficient mice display an enhanced prolifer-
ation of intestinal crypt cells, resulting in an overt megaintestine
phenotype in the upper small bowel, but neither gut inflammation
nor increased epithelial paracellular permeability are observed in
these mice, despite a decrease in the number of TJ strands within
the distal jejunum and without a compensatory increase in the
synthesis of other claudins (72). These observations suggest that
both occludin and claudin-15 may be involved in epithelial differ-
entiation/growth regulation, but likely do not play a critical role
in the regulation of intestinal epithelial permeability. Similarly,
transgenic mice expressing constantly active myosin light chain
kinase (CA-MLCK) show a marked increase in intestinal perme-
ability and overexpression of IFNγ, TNF, and IL-4, but no overt
histologic signs of intestinal inflammation. MLCK is a kinase that,
upon TNF stimulation, phosphorylates myosin II regulatory light
chain, leading to TJ rearrangement, and reduction of intestinal
barrier function. Interestingly, CD4+CD45RBhi adoptive transfer
into CA-MLCKRAG1−/− mice causes a much more severe colitis,
with an earlier onset, compared to transfer into RAG−/−mice (73).
Taken together, these data suggest that, perhaps, deletion, or
deficiency of a singly TJ protein may not be sufficient to dis-
rupt intestinal barrier function alone, and may require a particular
combination or a greater number of TJs to be altered and/or dys-
regulated before overt gut inflammation is observed. Alternatively,
the possibility exists that dysfunction of TJ assembly or TJs them-
selves may not be causal for the generation of chronic intestinal
inflammation.
The aforementioned animal models, although extremely useful
in investigating specific molecular mechanisms in the pathogenesis
of IBD, do not fully recapitulate disease observed in patients since
IBD is clearly multifactorial and not caused by a single mutation or
defect in cellular and molecular immune pathways. As such, ani-
mal models that occur spontaneously in the absence of chemical,
genetic, or immunologic manipulation are likely more represen-
tative of the human disease condition. Two animal models that
spontaneously develop chronic intestinal inflammation similar to
human IBD are the C3H/HeJBir and SAMP1/YitFc (SAMP) mouse
strains, and their phenotypes are likely due to multiple defects in
both innate and adaptive immune responses (7, 74). While gut
inflammation in both models appears to be due to multiple defects,
epithelial innate dysfunction also plays a central role in disease
pathogenesis of these two mouse strains. As previously described,
C3H/HeJBir show an impairment of epithelial innate immune
responses, especially against flagellin (8, 9), leading to overag-
gressive adaptive immune responses. The SAMP mouse strain is
another spontaneous model of IBD that most closely resembles
CD for its histologic features and localization to the terminal ileum
(74, 75). The ileitis characteristic of these mice is discontinuous
in nature, with inflammatory lesions occurring sporadically along
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length of the ileum, alternating with areas of relative normalcy, and
with a small percent of mice (2–3%) developing perianal fistulas
(76). Alterations in epithelial morphology and architecture occur
early in the disease process with expansion of IECs of primar-
ily secretory cells lineage, including Paneth cells and goblet cells,
and a decrease of mature absorptive enterocytes (77). Remarkably,
in vivo and ex vivo experiments using SAMP mice have shown
significantly increased epithelial paracellular permeability in the
ilea in comparison to control mice; increased gut permeability
was observed in both older mice with established inflammation,
and in young mice (3 weeks of age), before the onset of the dis-
ease (78). This epithelial barrier defect appears to be independent
of commensal bacterial colonization as increased permeability is
also observed in SAMP mice raised under germ-free conditions.
The increase in gut permeability is likely related to altered TJ pro-
tein expression and localization in that epithelial expression of
claudin-2 is eightfold greater than in controls, while occludin is
markedly suppressed, prior to the onset of intestinal inflamma-
tion. As such, the balance between different TJ proteins appears
to play a crucial role in regulating TJs assembly/stabilization, and
therefore, paracellular permeability. High expression of occludin
and of most claudin isoforms usually reinforces the intestinal bar-
rier; on the contrary, claudin-2 expression appears to establish
lower affinity interactions with other claudin isoforms on neigh-
boring IEC, leading to a leakier epithelial layer (79). The study
of the SAMP genome revealed several quantitative trait loci with
linkage to ileal inflammation, located on chromosomes 6, 8, 9, 17,
and X (80). Within these loci, several potential candidate suscep-
tibility genes have been identified, and most are involved in either
immune regulation and/or intestinal epithelial functions. Among
these, several were related to the structural formation of the apical
junctional complex, including E-cadherin (Cdh1) on chromosome
8, JAM-C (Jam3), cingulin-like 1 (Cgnl1), nectin-1 (Pvrl1) and
β-catenin (Ctnnb1) on chromosome 9, afadin (Mllt4) on chro-
mosome 17, and interestingly, claudin-2 (Cldn2) on chromosome
X (81). In addition to these data, further observations suggest
a primary involvement of IEC in the pathogenesis of the ileitis
characterizing SAMP mice; in fact, the primary defect appears
to originate from a non-hematopoietic source since bone mar-
row (BM) chimeras consisting of irradiated non-inflamed control
AKR recipients receiving donor pathogenic SAMP BM did not
confer disease, while recipient SAMP mice receiving donor AKR
BM resulted in severe ileitis (78). Taken together, these data suggest
that epithelial barrier dysfunction is likely the primary, initiating
trigger that leads to gut inflammation in the SAMP model of CD-
like ileitis as well as other experimental models of chronic intestinal
inflammation, and that is phenomenon may share similarities to
patients with IBD.
It should be pointed out, however, that SAMP mice (similar
to the C3H/HeJBir strain), demonstrate defects in more than one
component of normal mucosal immune function. In fact, mice
generated by crossing the RAG-2 KO mutation onto the SAMP
background, resulting in SAMP mice that lack mature T and B
lymphocytes, do not develop ileitis (unpublished results), indicat-
ing that despite the presence of the epithelial barrier defect, the
adaptive arm of the immune system is still required for the dis-
ease phenotype to occur. Therefore, the concept of “multiple hits”
or defects in interacting components of host mucosal immune
responses (i.e., of both innate and adaptive origin) is likely the
cause of chronic intestinal inflammation in the spontaneous
murine models of IBD, and is likely also necessary for the initiation
and perpetuation of disease observed in patients with IBD.
TJ PROTEIN IMPAIRMENT IN HUMAN IBD
In IBD patients, several lines of evidence suggest that gut perme-
ability changes could play a pivotal role in disease development; in
fact, a decrease in intestinal epithelial barrier function and altered
expression of TJ proteins have been observed in patients affected by
CD and UC and their relatives (82, 83). Moreover, it has also been
shown that in CD patients, an increase in epithelial permeability
precedes episodes of disease relapse and the onset of symptoms
by up to 1 year (84, 85). Interestingly, as observed in SAMP mice,
claudin-2, and occludin appear to be involved in these permeabil-
ity changes. IEC from IBD patients express much more claudin-2
and less occludin, claudin-3 and -4 in comparison with gut epithe-
lia from healthy controls, particularly in active UC patients (86,
87). These findings are further corroborated by the observation
that claudin-2 is markedly upregulated in the epithelium of dogs
affected by idiopathic lymphocytic-plasmacytic colitis, another
model of spontaneous intestinal inflammation (88).
In addition to expression data, genetic studies have also revealed
a potential link between genetic polymorphisms/mutations in TJ-
associated genes and the development of IBD. A recent large GWA
study, including more than 2300 cases and 5400 control subjects,
identified novel epithelial-related susceptibility genes for UC (89);
this study found the greatest association with HNF4A, a gene
encoding hepatocyte nuclear factor 4α, a transcription factor that
regulates the synthesis of several TJ, AJ, and desmosome proteins
(90). In fact, IEC-targeted deletion of HNF4A causes the perinatal
death of experimental mice, due to severe defects in embryonic
development of the gastrointestinal tract, characterized by the
absence of crypt formation, reduced epithelial cell proliferation,
and defective goblet cell maturation (91). In addition, conditional
deletion of IEC HNF4A showed increased intestinal permeabil-
ity and greater susceptibility to chemically induced colonic injury,
suggesting the importance of this gene in intestinal inflammation
(92). In the same GWA study, authors identified laminin β1 sub-
unit (LAMB1) and E-cadherin (CDH1) as possible susceptibility
genes for UC (89), corroborating the data on the dominant nega-
tive N-cadherin (62) and conditional IEC p120-catenin KO mouse
models (63).
Other IBD susceptibility genes identified thus far appear to
be primarily involved in TJ assembly. In fact, variants of myosin
IXB (MYO9B), partitioning defective protein 3 (PARD3) gene, and
membrane-associated guanylate kinase, WW, and PDZ domain-
containing protein 2 gene (MAGI2), were found to be associated
with UC, with a weaker association with CD for MYO9B and
MAGI2 (93–95). MYO9B encodes an unconventional myosin mol-
ecule involved in actin remodeling of epithelial enterocytes, and
in TJ assembly (96), while PARD3 and MAGI2 encode for adaptor
proteins also participating to this process (95). Interestingly, CD
patients, carrying MAGI2 variants associated with IBD, display
higher serum levels of antibodies against antigens from intestinal
microorganisms, such as anti-Saccharomyces cerevisiae (ASCA),
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anti-CBir1 flagellin (CBir1), and anti-outer membrane porin C
(OmpC) (94), further confirming the central role of intestinal
barrier function in the pathogenesis of IBD. It is worth noting
that MYO9B, PARD3, and MAGI2 were also reported to be celiac
disease susceptibility genes (95, 97). If that is the case, a com-
mon, primary causal mechanism involving epithelial permeability
defects may be hypothesized as a potential trigger for the devel-
opment of chronic intestinal inflammation, as recapitulated in
Figure 3. Again, it would be fair to say that in human disease,
as postulated by the “multiple hit” theory, impairment of intesti-
nal permeability may represent only one of the aberrancies that,
if combined with others, can lead to the development of chronic
intestinal inflammation, such as that observed in IBD.
EPITHELIAL CELL INTEGRITY
The integrity and function of IECs appear to be additional deter-
minants in intestinal barrier function. As such, alterations in
structural proteins or in proteins that are pivotal in maintaining
cell homeostasis may lead to a breakdown of the epithelial “wall,”
as summarized in Figure 4. The profound dysfunction in IECs
caused by the loss of cell polarity has the ability to trigger potent
inflammatory responses within the gut. In fact, the onset of spon-
taneous chronic colitis has been described in mice deficient in
Ap1m2, a master regulator of IEC polarization; these mice display
impaired epithelial innate immune functions, as a consequence of
a reduction in β-defensin release, followed by a pathogenic Th17
immune response (98). Inflammation also develops when nor-
mal IEC turnover is disrupted, as in the case of recombination
signal protein for Ig κ J region (RPB-J); this protein is involved
in the regulation of the Notch signaling pathway, which plays a
major role in the regulation of intestinal epithelium differentia-
tion and proliferation. The conditional KO of RBP-J in IECs results
in the development of a spontaneous Th17 dominant colitis, char-
acterized by impaired epithelial defense against bacteria, goblet
cell hyperplasia, retarded IEC turnover, and altered TJ assembly
(99). In addition, the onset of intestinal inflammation can by initi-
ated by targeting the endoplasmic reticulum (ER) stress response,
which is pivotal for the development and survival of secretory
cells. Mice deficient in the transcription factor, X-box-binding
protein 1 (XBP1), a key component in the activation of the ER
stress response, spontaneously develop small intestine inflamma-
tion, which displays a patchy pattern, is not granulomatous, and
has severity varying from the presence of mild polymorphonuclear
infiltrates in lamina propria to the presence of crypt abscesses and
ulcerations (100). Striking features of these mice are the complete
ablation of functional Paneth cells, a marked reduction in number
and size of small intestine goblet cells, and villus shortening with
a reduced villus:crypt ratio, which are a sign of the regenerative
response. In the absence of XPB1, Paneth cells are unable to process
and secrete the anti-bacterial peptides and undergo early apopto-
sis, while small intestinal, but not colonic, goblet cells present with
a reduced number of secretory granules and low levels of MUC2
expression (100). Notably, these mice do not exhibit alteration in
intestinal permeability, but are much more susceptible to Listeria
monocytogenes infection compared to WT littermates, showing a
10-fold higher burden of L. monocytogenes translocating into liver
FIGURE 3 |The intestinal epithelial barrier plays a central role in gut
homeostasis. IECs form an semi-permeable lining, with barrier function
modulated by the presence of TJs, AJs, and desmosomes. Expression and
assembly of these protein complexes are finely regulated by several
intracellular pathways. Polymorphisms in MYO9B, PARD3, and MAGI2 and
impairment of the Gαi2/adenylate cyclase axis result in defective TJ
assembly; phosphorylation of myosin II through MLCK activation by TNF
leads to TJ disassembly. Lack of junctional proteins, such as JAM-A, or
altered expression and/or pairing (e.g., dominant negative N-cadherin,
claudin-2 overexpression) leads to increased epithelial permeability,
facilitating translocation of luminal bacteria, and antigens and exposure to
the mucosal adaptive immune system.
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FIGURE 4 | Role of epithelial cell integrity and mucus production in gut
health and disease. Proteins regulating cell structure (e.g., DLG5) or
metabolic functions (e.g., XBP1) maintain IEC integrity. IECs in constant
contact with luminal toxins and xenobiotics dispose of these harmful
molecules by means of several transporter proteins, such as MDR1, OCTN1,
and 2. IECs secrete a thick layer of mucus, whose production is finely
regulated by different proteins, including MUC family members and POFUT1.
Loss of control over ER stress, resulting from XBP1 dysfunction and
accumulation of toxic molecules inside IECs, secondary to transporter
molecule loss of function, cause IEC damage, defective defensin secretion
from Paneth cells, and release of proinflammatory mediators leading to
immune activation. Direct exposure of IEC to luminal toxins/antigens is
increased by deletion of MUC2, 3, and 4, which leads to dramatic reduction of
mucus production, and eventually to intestinal inflammation. Conversely,
overproduction of mucus is also harmful, leading to bacterial overgrowth in
intestinal crypts, as seen in POFUT1 deficiency, causing a dysregulation of
the epithelial transcription factor, NOTCH that controls IEC proliferation and
differentiation.
and spleen 72 h after oral infection (100). Therefore, in XBP1 KO
mice, the impairment of Paneth cell function, and the consequent
defect in bacterial clearance, appears to be the prominent trigger
for intestinal inflammation, rather than epithelial leakiness due
to suffering IECs. However, the lack of inflammation and crypt
colonization by intestinal microbes in Paneth cell or cryptidin
deficient mice (101) suggests that other defects are required in
order to initiate intestinal inflammation. In fact, silencing of XBP1
in the murine IEC line, MODE-K, leads to the activation of Jun
N-terminal kinase (JNK)/Stress-activated protein kinase (SAPK)
signaling, enhancing IEC inflammatory responses to proinflam-
matory stimulation, such as flagellin or TNF (100). Thus, ER stress
due to knocking down XPB1 directly puts IECs into a proinflam-
matory state. Even though the XPB1 KO phenotype consists of
ileitis, colonic IECs are also prone to ER stress and are, in fact,
more sensitive to harmful events. As such, these mice are much
more susceptible to DSS colitis than WT controls, exhibiting more
severe clinical and histological signs of disease activity after the
DSS challenge (100). Finally, XPB1 may also play a major role in
human IBD as inflamed and non-inflamed tissue biopsies from
CD and UC patients show an increased expression of this tran-
scription factor (100). In addition, several SNPs in XPB1 have
been shown to be associated with both CD and UC (100), strongly
indicating the involvement of XPB1 in human IBD pathogenesis.
The murine multiple drug resistance 1 a (mdr1a) gene, corre-
sponding to human MDR1, encodes P-glycoprotein 170, which
is an efflux pump for amphipathic and hydrophobic molecules,
mainly xenobiotics, and is expressed in many cell lineages, includ-
ing IECs (102). This molecule participates in the transmembrane
transport of macromolecules, thus regulating epithelial transcel-
lular permeability, but also in cellular detoxification processes.
The importance of P-glycoprotein 170 in preserving intestinal
www.frontiersin.org September 2013 | Volume 4 | Article 280 | 11
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pastorelli et al. Intestinal epithelium regulates mucosal immunity
homeostasis is depicted in mdr1a KO mice, wherein the lack
of this protein causes development of spontaneous and severe
colonic inflammation. The colitis phenotype, which closely resem-
bles human UC, is characterized by massive thickening of the
mucosa, leukocyte infiltration in the lamina propria, occasional
crypt abscesses and ulcerations, crypt elongation, and dysregulated
IEC growth (103). Not surprisingly, these mice display signs of
intestinal barrier dysfunction. In fact, increased bacterial translo-
cation that correlates to disease severity, greater basal colonic
ion transport, decreased TER, are typical features of these mice.
Indeed, the increase in epithelial permeability does not appear to
be a consequence of the inflammation since it is observed as early
as 4 weeks of age, prior to the onset of colitis (104). Moreover, the
development of the disease requires the presence of the normal gut
flora, as antibiotic treatment virtually prevents intestinal inflam-
mation (103). Indeed, the genetic background greatly influences
the development of the inflammatory phenotype; in fact, whereas
mdr1a deficiency in FVB mice causes spontaneous colitis, the same
genetic defect triggers colonic inflammation only in C57/BL6 mice
when they are exposed to DSS (105). Gender also plays an impor-
tant role in this model, as male mdr1a deficient mice develop severe
colitis earlier and show increased epithelial permeability compared
to females. In addition, barrier dysfunction is accompanied by
decreased phosphorylation of the TJ proteins, occluding, and ZO-
1. Interestingly, a recent study showed that colons from young, 4-
to 5-week-old mdr1a deficient mice are disease-free and display no
evidence of increased permeability compared to controls (106). In
these mice, a distinct pattern of upregulated genes was observed in
local tissues that are associated with bacterial recognition and the
ubiquitin-proteasome system, suggesting that P-glycoprotein may
be critical in regulating interactions with the enteric microflora
leading to colitis, albeit prior to epithelial barrier disruption. Sim-
ilarly to SAMP mice, the generation of BM chimeras in this model
also strongly indicates an inherent epithelial defect as a primary
mechanism for the development of colitis. In fact, irradiated non-
inflamed control FVB recipients receiving donor pathogenic BM
from mdr1a KO mice BM did not show signs of disease, while
recipient mdr1a KO mice receiving donor BM from FVB mice
developed overt colitis. Taken together, these data suggest that the
initiating factor for the development of colitis in mdr1a KO mice
is likely the result of an epithelial-derived dysfunction; however,
controversy remains as to whether the primary event is solely due
to a permeability defect, given the expression of P-glycoprotein
170 in hematopoietic cells as well.
In support of the relevance of this transporter in gut inflamma-
tion, a polymorphism (Ala893) of MDR1 has been reported to be
associated to IBD (107). Likewise, IBD genetic studies identified
two genes, encoding epithelial transporter proteins, as IBD sus-
ceptibility genes. Solute carrier 22A4/organic cation transporter
1 (SLC22A4/OCTN1) and SLC22A5/OCTN2, localized on chro-
mosome 5, encode transporter proteins involved in xenobiotic
and toxin removal, physiological substrate uptake, and carnitine
metabolism (108). Functional nucleotide polymorphisms (SNPs)
of these genes, leading to impairment of OCTN promoter activity
and consequently to severe alterations in transporter functions,
were found to confer susceptibility to the development of CD
(109). Therefore, it could be hypothesized that the carriage of
MDR1, OCTN1, and OCTN2 variants might interfere with IEC
homeostasis at different levels: variants of all three of these genes
could alter transepithelial permeability to large molecules, carriage
of the MDR1 polymorphism could dampen the ability of IEC to
eliminate potentially toxic molecules, while OCTN1 and OCTN2
SNPs could damage mucosal energetic metabolism through a
defective carnitine intake.
Other genetic variants that may affect the integrity of IEC struc-
ture and polarity could represent alternative predisposing factors
for the onset of IBD. In fact, variants of the gene encoding the
structural protein Disk large homolog 5 (DLG5) appear to predis-
pose individuals to CD (110). DLG5 is located on chromosome
10 and encodes a scaffolding protein expressed in IEC from both
the colon and small bowel, and is involved in the maintenance of
IEC integrity, regulation of cell growth, as well as epithelial polar-
ization (111). Haplotype D, or R30Q variant (SNP 113G→A),
influences CD susceptibility as it encodes an amino acid substi-
tution that results in a mutation that likely interferes with DLG5
scaffolding (110). Similar to MYOIXB, PARD3, and MAGI2 vari-
ants, the DLG5 R30Q polymorphism has also been reported to be
associated with celiac disease (112), corroborating the concept that
a common mechanism, that is breakdown of the intestinal barrier,
may exist between celiac disease and IBD. In addition to the scaf-
folding function, which also involves the constitution of AJs, DLG5
is also important in innate immune responses. Recent studies have
identified an exon, which encodes for a CARD domain, that has
been identified within the DLG5 gene and its expression in colonic
tissues has been confirmed (113). As such, DLG5 may belong, or
be closely related to, the CARD/NOD family, and therefore, may
also participate directly in bacteria-host interactions within the
gut. Interestingly, data generated in pediatric and adult IBD pop-
ulations showed a gender effect in analyzing DLG5 R30Q carriage
and CD susceptibility. While this haplotype represents a suscep-
tibility factor for CD in males, it confers protection against the
development of disease in females (114, 115). Further studies,
however, are warranted to investigate whether gender differences
exist and to mechanistically determine how DLG5 is involved in
IBD pathogenesis.
GENETIC REGULATION OF EPITHELIAL MUCUS PRODUCTION
Aside from their absorptive, immunological, and barrier functions,
IECs are also specialized to produce a large amount of mucus. As
such, the epithelial mucosal surface is covered by a more than
100µm thick layer of mucus, secreted by goblet cells (116). The
purpose of this mucus layer, aside from the lubrication between
the luminal contents of the gut and the epithelial surface, is to add
further protection to the intestinal barrier. The main constituents
of mucus are phospholipids and mucins, both of which are highly
negatively charged; therefore, the mucus layer represents both a
mechanical and chemical barricade overlying the IEC lining. In
addition, the mucus layer also supports the presence of proteins
in close proximity to the intestinal wall that are pivotal in con-
trolling luminal bacterial burden, such as secretory IgA (117) and
lactoferrin (118).
Goblet cells may also play a primary role in the activation of
the intestinal inflammatory process. Goblet cells contain potent
regulators of the inflammatory cascade, such as components of
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the kallikrein-kinin system, within their cytoplasmic secretory
granules. Kallikrein is an enzyme present in different isoforms, in
plasma, and in tissues that cleaves high molecular weight kinino-
gen to release bradykinin and activates both coagulation and
inflammatory events (119). Conversely, kallistatin, a member of
the serine proteinase inhibitor family, is its specific antagonist
(120). Tissue expression of kallikrein and kallistatin significantly
varies in active IBD; in fact, localization in normal intestinal tis-
sues, in non-involved area of IBD patients, and in specimens from
diverticulitis patients, is confined to the cytoplasm of intestinal
goblet cells. During the specific inflammatory process character-
izing active IBD, goblet cells are depleted of both kallikrein and
kallistatin, which are, instead, massively present in the interstitium
(121, 122). Thus, goblet cells appear to actively secrete kallikrein
and kallistatin in the interstitium, directly regulating local gut
inflammatory responses.
Similar to that observed with other components that are impor-
tant in maintaining intestinal barrier function, dysfunction of
mucus production may also lead to intestinal inflammation. For
example, while MUC2 KO mice lack the complete gene for MUC2
mucin (123), different strains of MUC2 mutant mice, Winnie
and Eeyore, are characterized by two distinct non-complementing
missense mutations in MUC2 (124). The different mouse strains
spontaneously develop colitis, exhibiting watery diarrhea, rec-
tal bleeding, and prolapse. Histological features include mucosal
thickening, superficial erosions, crypt elongation, goblet cell loss,
neutrophilic infiltration, and crypt abscesses. Surprisingly, the col-
itic phenotype of Winnie and Eeyore mice appears to be worse
and more penetrant than MUC2 KO mice, the latter being present
only under certain genetic backgrounds (124). This phenomenon
could be explained considering that the mutations in Winnie and
Eeyore mice cause MUC2 protein misfolding and a consequential
accumulation in the cytoplasm leading to ER stress (124). This
observation, again, highlights the importance of the “multiple hit”
concept, since the complete lack of MUC2, predisposing to bowel
inflammation, is not sufficient to initiate the cascade of molecular
events leading to intestinal inflammation. If the impairment of
the mucus barrier is associated with other pathogenic noxae, for
example, the disease manifests itself in full.
In fact, reduced production of MUC2 has been reported in
human IBD, particularly UC, although it is not well understood
whether this decrease represents a primary defect or if it is sec-
ondary to the epithelial damage induced by inflammation (125).
However, genetic polymorphisms involved in the regulation of
mucus production have also been associated with human IBD. In
particular, it has been suggested that a few, rare variable number of
tandem repeat (VNTR) alleles of the human intestinal mucin gene,
MUC3, and non-synonymous SNPs of MUC3A, which is part of
the MUC3 gene and encodes a membrane-bound mucin with epi-
dermal growth factor (EGF)-like motifs that alter IEC signaling,
may confer a genetic predisposition to UC (126) and CD (127),
respectively. Thus, impairment of the bowel mucosal barrier, due
to different MUC3A variants, may be involved in the pathogenesis
of both UC and CD. On the other hand, an hyperproduction of
mucus, leading to an alteration of mucus-associated flora has been
implicated as the basis for the enterocolitic phenotype presented
by mice with selective deletion of protein O-fucosyltransferase 1
(Pofut1) in IECs (128). POFUT1 is an enzyme required for cor-
rect signaling of the Notch pathway. Mice defective in IEC-specific
POFUT1 display marked hyperplasia and hypertrophy of goblet
cells in both the small intestine and colon, leading to an over-
secretion of mucus. Other features of these mice are Paneth and
enteroendocrine cell hyperplasia (128). At 4 weeks of age, these
mice start to develop ileal and colonic inflammation, evident by
thickening of the intestinal wall and by an increase in intesti-
nal permeability. Inflammation increases until 36 weeks of age,
with 100% penetrance at this age. The enterocolitis is histologi-
cally characterized by crypt hyperplasia, inflammatory infiltrates
within the lamina propria, crypt abscesses, and transmural inflam-
mation. Moreover, significantly high levels of Th1 and Th17
cytokines are detectable in the inflamed tissues, while a shift
toward Gram-negative bacteria is evident in the gut microflora,
with spiral-shaped organisms accumulating in dilated and mucus
filled crypts (128).
In further support of intestinal mucus production playing a piv-
otal role in maintaining gut homeostasis, is the observation that
thickening of mucus secretions, secondary to the common cys-
tic fibrosis transmembrane conductance regulator (CFTR)∆F508
mutation, appears to confer protection against the development
of CD. In fact, heterozygosity for this mutation has recently been
shown to be negatively associated with CD in two independent
European cohorts, but had no impact on the risk of develop-
ing UC (129). CFTR encodes a transmembrane transporter that
pumps chloride anions out of the cell, regulating both secretory
and absorptive functions, and the production of mucus from IECs;
however, it can also bind the TLR4 ligand, LPS, impacting on
the interactions between IECs and bacteria. The ∆F508 muta-
tion causes loss of one phenylalanine from the CFTR amino acid
sequence and consequently, the misfolding of this protein. This
mutation completely eradicates the functional activity of CFTR,
and therefore TER is increased, while PRR signaling remains intact
(129). The fact that carriage of one allele of this mutation con-
fers protection against CD further underscores the importance of
genetic contributions in regulating epithelial barrier function, as
well as intestinal permeability and epithelial innate responses, in
maintaining normal mucosal immune homeostasis.
THERAPIES THAT ENHANCE INTESTINAL BARRIER
FUNCTION IN IBD
Since emerging evidence in recent years has implicated the impor-
tance of intestinal barrier function in maintaining gut immune
homeostasis, increasing efforts and investment in developing tools
by which to manipulate epithelial innate immunity and permeabil-
ity have been made in order to obtain therapeutic effects in human
disease. At present, several approaches have been made and/or
proposed to enhance intestinal barrier function using several dif-
ferent strategies. Such drug development could boost epithelial
innate immunity, decrease the permeability of the epithelial bar-
rier, or improve the quality and quantity of mucus production
(Figure 5).
ENHANCERS OF EPITHELIAL INNATE IMMUNITY
The use of granulocyte-monocyte colony stimulating factor (GM-
CSF), or Sargramostim, has been proposed for the treatment of
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FIGURE 5 |Therapeutic agents that enhance epithelial barrier
function. Several drugs can potentially improve different components of
intestinal barrier function by (from left to right): (1) enhancing mucosal
innate immunity through increased expression of TLRs and production of
anti-microbial peptides, (2) decreasing epithelial permeability through the
expression and assembly of TJ and AJ proteins, and (3) restoring epithelial
cell and mucus layer integrity by reducing IEC apoptosis and inducing
mucus production.
patients suffering from CD. A randomized placebo controlled clin-
ical trial demonstrated a significant improvement in disease activ-
ity in patients treated with GM-CSF compared to those treated
with placebo (130), even though the clinical remission rates did
not differ in the two groups. As such, instead of serving as an
immunosuppressant or anti-inflammatory agent, GM-CSF has
been proposed to serve an enhancer of innate immune responses
and has been used for the treatment of inflammatory diseases. This
paradox may be explained by considering that GM-CSF is capable
of boosting innate immune functions, and therefore, may reinforce
the intestinal mucosal barrier (131). In fact, GM-CSF stimulation
increases neutrophil expression of PRRs (132), and neutrophil,
monocyte, and macrophage bactericidal activity (133). At present,
most of the data regarding GM-CSF’s effects on innate immunity
come from experiments involving hematopoietic cells since it has
been shown that IECs, including Paneth cells, display receptors
for GM-CSF, and proliferate after GM-CSF stimulation (134). It
is therefore plausible that GM-CSF may have a direct influence on
IEC barrier function.
Several lines of evidence also suggest that probiotics can modu-
late host epithelial innate immune responses. Indeed, it is believed
that probiotics have the ability to stimulate mucosal defenses
through TLRs and upregulation of innate-type cytokines (135,
136). For example, experimental data has shown that adminis-
tration of Lactobacillus casei has the ability to potently increase
cellular expression of TLR2 (137), and the E. coli strain, Nissle
1917, can induce the expression of β-defensins (138), as well as
both TLR2 and TLR4 (139). Moreover, E. coli strain Nissle 1917
has been shown to ameliorate DSS colitis in C57BL/6 WT mice, but
not in mice deficient in TLR2 or TLR4, suggesting that activation of
both TLR2 and TLR4 signaling is pivotal for this microorganism in
order to exert its beneficial effects (139). Enhancement of innate
immune function is not the only way by which probiotics may
aid in the control of intestinal pathogens; probiotic supplemen-
tation can alter the microflora of IBD patients (140) through
competition with enterotoxigenic and enteropathogenic bacteria
for energy sources and for IEC surface receptors. In this way, pro-
biotics may block binding of pathogens to the intestinal epithelial
surface, inhibiting their invasivity, and thereby reducing potential
bacterial translocation (141, 142).
DRUGS THAT DECREASE EPITHELIAL PERMEABILITY AND LEAKINESS
The modulation of TJ protein expression may also represent a
promising target for novel therapies for the treatment of inflam-
matory gut disorders. At present, the use of compounds with the
ability to enhance TJ expression and function has already been
proposed for celiac disease. Indeed, celiac disease shares several
features with IBD, including an increase in intestinal permeabil-
ity, and as mentioned earlier, a few susceptibility genes involved
in TJ assembly. An octapeptide, called AT-1001, derived from Vib-
rio cholera’s zonula occludens toxin (ZOT), has been proposed
for the treatment of celiac disease. This peptide has the ability to
interfere with IEC cytoskeleton rearrangement and TJ disassembly,
secondary to gliadin exposure (143). Thus, AT-1001 antagonizes
the increase in paracellular permeability induced by ZOT analogs,
and the effect of gliadin on epithelial permeability in the duode-
nal mucosa of celiac patients (143). In addition, IL-10 KO mice
that develop spontaneous colitis displayed less severe intestinal
disease when treated with AT-1001 (144). Therefore, the ratio-
nale for the use of AT-1001 in gut inflammatory disorders has
become quite apparent. Currently, only two randomized placebo-
controlled safety and dose-ranging studies, involving 20 and 86
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celiac disease patients, have been performed, demonstrating the
safety and tolerability of this molecule and its ability to reduce
intestinal permeability (143, 145). Larger clinical studies are war-
ranted in order to thoroughly evaluate the therapeutic value of
this octapeptide in celiac disease, and possibly, in IBD.
Vitamin D has also been shown to have the potential of reducing
epithelial permeability and ameliorating mucosal inflammation in
IBD. Vitamin D induces the expression of several TJ proteins, such
as ZO-1, claudin-1, claudin-2 (146), as well as the AJ protein,
E-cadherin (147). Vitamin D is also able to increase the TER in
monolayers of Caco-2 cells by augmentation of junction protein
expression (146), demonstrating a functional effect. In addition,
knockdown of the Vitamin D receptor (VDR) gene in Caco-2 cells
causes a marked reduction in IEC TJ expression and function,
while VDR KO mice are more susceptible to DSS-induced colitis
and exhibit more severe inflammation compared to WT litter-
mates. These mutant mice display delayed and impaired wound
healing and a significant reduction in colonic TER following DSS
challenge, which is related to the marked destruction of TJ com-
plexes (146). Remarkably, carriage of VDR genetic polymorphisms
has been associated with the development of human IBD in dif-
ferent populations (148, 149). Thus, Vitamin D appears to play a
critical role in maintaining intestinal barrier function, although
further data are needed to rationalize its clinical use in patients
with IBD.
Sex hormones, as well, may play an important role in the
modulation of immune responses and intestinal permeability.
It is well established that the prevalence of inflammatory and
autoimmune disorders is higher in female than in male sub-
jects (150), and this gender bias is present, albeit to a much
lesser extent, in IBD patients. In fact, CD is slightly more
common and aggressive in female compare to male patients
(151). However, how estrogens and androgens can modify
mucosal immune responses still remains somewhat obscure. The
administration of dehydroepiandrosterone and 7-alpha-hydroxy-
dehydroepiandrosterone in rats with TNBS colitis attenuated the
degree of mucosal damage and inflammation (152); surprisingly,
despite the potential role of estrogens in triggering autoimmunity,
17alpha-ethynyl-17beta-estradiol also ameliorated the severity of
disease in HLA-B27 transgenic rats, which spontaneously develop
colitis (153). One possible explanation is differential signaling
through the estrogen receptors (ER), ERα, and ER-β. Interestingly,
it has been demonstrated that activation of ERβ on IECs, through
estradiol or specific agonists, increases epithelial barrier function
by upregulating occludin and JAM-A, both in vitro and in vivo
systems (154). Thus, alterations in TJs triggered by selective ERβ
activation may be protective against the development of intestinal
inflammation, suggesting a possible role of ERβ agonists in the
treatment of IBD.
Parenteral heparin and low molecular weight heparins
(LMWHs), such as tinzaparin, deligoparin, enoxaparin, reviparin,
and dalteparin, have been proposed as a therapeutic option in IBD,
primarily due to their anti-inflammatory properties. Their actual
efficacy, however, is debatable, at least considering the parenteral
administration route (155). Data recently obtained using chemi-
cally induced colitis models suggest a potential role of two differ-
ent LMWHs in ameliorating gut inflammation if administered
directly on the epithelial surface. In one study, parnaparin, a
LMWH of 5000 kD, was administered to rats intracolonically, and
improved disease severity (156). In another study, colitic mice
treated with microspheres loaded with enoxaparin (4500 kD),
specifically designed to release the drug into the colon, resulted in a
reduction of inflammatory activity after parenteral administration
(157). The same approach was tested in a pilot study in patients
with mild to moderate active distal UC; sodium parnaparin, dis-
persed in a multimatrix formulation (MMX) in order to obtain a
controlled colonic-release of the drug, showed no side effects and
possible efficacy (158). A later, randomized, placebo-controlled
clinical trial validated these results, showing a significant clinical
response in parnaparin- vs. placebo-treated patients (159). The
potential efficacy of heparins may be explained not only by their
primary anti-inflammatory properties, but also their ability to reg-
ulate epithelial permeability. In fact, the lack of heparan sulfate
and syndecan-1, two proteoglycans belonging to the heparinoid
compound family, from the basolateral surface of IECs is closely
linked with protein-losing enteropathy (PLE), a syndrome, charac-
terized by the leakage of proteins into the intestinal lumen through
the gut wall (160–162). Knockdown of syndecan-1 causes aug-
mented paracellular permeability in in vitro monolayers of the
HT29 colon cancer cell line, while heparan sulfate and syndecan-1
deficient mice display increased intestinal protein loss that can be
prevented by the parenteral administration of heparins, including
2,3-de-O-sulfated heparin, which does not have any anticoagulant
properties (163).
Probiotics, as well, appear influence epithelial paracellular per-
meability, as indicated by the increased TER obtained following
treatment of in vitro intestinal epithelial monolayers (164). The
mechanism(s) by which intestinal permeability is decreased fol-
lowing probiotic treatment involves rearrangement of TJ proteins,
such as ZO-2, protein kinase C ζ (PKCζ) and occludins, that are
pivotal in stabilizing TJ complexes (165, 166). It has also been
shown that probiotics can decrease intestinal permeability, in vivo,
during chemically induced colitis, restoring gut barrier integrity
through the maintenance of TJ protein expression, and the pre-
vention of IEC apoptosis (167). Accordingly, VSL#3, a multiple
probiotic formulation, proved to be efficacious in restoring early
epithelial permeability defects in young SAMP mice, prevent-
ing/delaying the development of intestinal inflammation. This
effect appears to be related to the increase of TNF production
by IECs (168); in fact, co-administration of VSL#3 and anti-TNF
antibodies significantly dampened the efficacy of probiotics (169).
Thus, increased TNF production by IECs induced by probiotics,
may enhance different components of mucosal innate immunity
and/or epithelial barrier function.
RESTORATION OF EPITHELIAL CELL INTEGRITY AND BIOLOGY
The integrity of IECs themselves, their cell membrane, and the
mucus layer covering the epithelium of the entire gastrointestinal
tract, are of paramount importance in maintaining gut immune
homeostasis. Indeed, a defect in mucus production has been
suggested as a primary feature of UC since the 1980s (170).
Anti-TNF monoclonal antibody therapies have shown great
efficacy in obtaining and/or maintaining clinical and endoscopic
remission in patients with IBD (171). Aside from their potent
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immunomodulating effects, anti-TNF antibody administration
has the ability to restore mucosal barrier integrity, normaliz-
ing intestinal permeability, in CD patients (172, 173). According
to experimental data from studies on human endoscopic biop-
sies (174) and on SAMP mice (175), this effect could be related
to homeostatic regulation of mucosal cell apoptosis induced by
anti-TNF strategies. Similarly, manipulation of the enteric flora
may provide an alternative strategy to increase epithelial barrier
integrity by inducing anti-apoptotic processes. Administration
of specific commensal E. coli in a mouse model of intestinal
development was shown to prevent staurosporine-induced apop-
tosis, increasing the tissue expression of IFNαA and guanylate
binding protein-1 (GBP-1), a recently identified anti-apoptotic
protein (176).
Growth factors and mediators that promote mucosal wound
healing have also been proposed to enhance epithelial barrier
integrity by inducing epithelial repair and restitution processes.
EGF, for example, has been proposed and tested as a potential
therapeutic agent for the treatment of UC. The addition of EGF
enemas to mesalamine treatment in UC patients has been shown
to increase the response rate to the therapy, confirming the impor-
tance of enhancing mucosal integrity for IBD patients (177). In
addition, as mentioned earlier, trefoil factors are proteins synthe-
sized by IECs that initiate and improve wound healing after a
mucosal injury. Selective deletion of TFF3, abundantly produced
by goblet cells in both the large and small intestine, increases
the susceptibility to chemically induced colitis (178). Interestingly,
exogenous administration of TFF3 was able to reverse colitis, sug-
gesting a potential role of TFF3 in IBD management (178). As such,
a pilot clinical trial using human recombinant TFF3 enemas as a
novel therapeutic strategy for the treatment of UC was performed
(179); this trial, however, did not show any significant difference
between patients treated with topical TFF3 in combination with
oral 5-ASA vs. those treated with oral 5-ASA alone. Therefore,
further studies, perhaps with different clinical conditions or with
different administration routes are needed in order to investigate
the true therapeutic value of this molecule.
The intestinal barrier can also be structurally manipulated
through modification of the IEC membrane composition. Admin-
istration of sphingomyelinase decreases TER in monolayers of
Caco-2 cells (180) through the hydrolysis of IEC membrane sphin-
gomyelin into ceramide (181), thus altering the composition of
cholesterol and sphingolipids in TJ membrane microdomains
(182) and transmembrane signaling (180). The end result of
this complex chain of molecular events leads, in the end, to an
increase in paracellular and transcellular epithelial permeability.
Similarly, intestinal epithelial permeability is directly modified by
cell membrane lipid content (183–185). As such, omega-3 polyun-
saturated fatty acids have been proposed as an adjuvant therapy
in IBD (186, 187), even though their efficacy in inducing and
maintaining remission is still debatable (188, 189). Interestingly,
recent randomized and controlled clinical trials showed that the
administration of phosphatidylcholine by slow release amelio-
rates the inflammatory activity in UC patients, also in steroid
refractory subset of patients (190, 191). The rationale behind
this rather new therapeutic approach is that phosphatidylcholine
and other phospholipids (192) serve as major components of
the intestinal mucus layer, generating a hydrophobic protec-
tive layer overlying IECs, and therefore take part in establish-
ing the gut mucosal barrier. Mucus from UC patients has been
shown to be defective in phosphatidylcholine compared to con-
trols and CD patients (192); thus, this deficiency could be of
pivotal importance in the pathogenesis of disease since it sig-
nificantly alters colonic barrier functions. In addition, intestinal
mucus production can be boosted by the administration of cathe-
licidin, an anti-microbial peptide secreted by IECs. Cathelicidin
has been given intrarectally to mice challenged with DSS; in this
experiment, mice treated with cathelicidin displayed increased
mucus production, an overexpression of the mucin genes MUC1,
MUC2, MUC3, and MUC4, and milder colitis than untreated
controls (193). The ability of cathelicidin to induce mucin gene
expression has been confirmed, in part, in the colonic epithe-
lial cell line, HT-29, which responded by upregulating MUC1
and MUC2, but not MUC3 and MUC4 (193). Therefore, aside
from its bactericidal activity, cathelicidin may have the poten-
tial to treat colitis due to its effect on enhancing gut mucus
production.
Similar to cathelicidin, butyrate, a short chain fatty acid pro-
duced by intestinal microbial fermentation of dietary fibers, has
the ability to reinforce epithelial barrier function through an
increase in mucus production. In fact, administration of butyrate
to human colon cancer cell lines or to endoscopic colon biopsies
clearly upregulates mucin production (194, 195), while intrarectal
delivery of butyrate into rats increased colonic mucus secretion
(196). As such, several studies suggest a primary role of butyrate
in the modulation of epithelial permeability. Butyrate can increase
TER in Caco-2 and HT-29 cell monolayers by augmenting TJ
protein expression (197, 198); however, this effect appears to be
dose and cell type dependent. In fact, a higher concentration of
butyrate increased paracellular permeability in Caco-2 monolay-
ers (198) and in rat distal colon specimens (199). Interestingly,
butyrate exerts many other effects on IECs, specifically contribut-
ing to the energetic balance of cells, controlling oxidative stress,
and in regulating the inflammatory status of cells (200). Its role in
maintaining the epithelial barrier may be more complex, including
several pivotal functions for the preservation of IEC homeostasis
and integrity. Currently, it is unclear which of these many actions
confers the most potent therapeutic effect induced by butyrate
administration (201, 202).
In summary, several therapeutic agents demonstrate the poten-
tial of modifying the intestinal barrier and enhancing various
IEC functions. Their true clinical efficacy in the management of
chronic intestinal inflammatory disorders, however, is still largely
unknown. This is primarily due to the lack or scarcity of evidence-
based information and data regarding the effectiveness of these
compounds for the treatment of intestinal inflammation. There-
fore, while a deeper knowledge of the cellular events leading to
the impairment of mucosal barrier function and the onset of
gut inflammation is needed, more safety and efficacy trials are
warranted to assess the feasibility of manipulating the intesti-
nal barrier as a novel therapeutic approach for the treatment of
chronic inflammation in the GI tract.
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CONCLUSION
The etiology of IBD is complex and as researchers deepen their
knowledge regarding the mechanisms underlying the patho-
genesis of chronic intestinal inflammation, emerging evidence
has revealed that the intestinal epithelium plays a central role.
Defects of primary epithelial etiology leading to chronic gut
inflammation globally include dysfunction of innate immune
responses and of epithelial barrier integrity. However, it is
likely that the development of IBD occurs as the result of a
concomitant presence of different defects in various compart-
ments, as postulated by the “multiple hit” theory, and as sup-
ported by several mouse model of chronic intestinal inflam-
mation. As such, impairment of normal intestinal epithelial
function, although likely not sufficient by itself to sustain the
inflammatory process, plays a primary role in the onset and
maintenance of disease. Further investigation is needed to define
its precise role in the pathogenesis of IBD, which will lead to
more targeted therapies and strategic approaches to specifically
boost intestinal epithelial function to ultimately treat patients
with IBD.
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